CK Life Sciences International Holdings (STU:LSI) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
CK Life Sciences International Holdings EBITDA Margin % Related Terms
CK Life Sciences International Holdings EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CK Life Sciences International Holdings EBITDA Margin % Chart
CK Life Sciences International Holdings Annual Data
STU:LSI vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, CK Life Sciences International Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CK Life Sciences International Holdings EBITDA Margin % vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CK Life Sciences International Holdings (STU:LSI) has a EBITDA Margin % of 10.10% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CK Life Sciences International Holdings and its competitors. This is 12% below median its historical median of 11.52. Over the past decade, CK Life Sciences International Holdings' EBITDA Margin % has ranged from 6.19 to 13.17. According to the industry distribution chart, CK Life Sciences International Holdings ranks #267 out of 945 companies in the Biotechnology industry, placing it in the top 28.3%.
Is CK Life Sciences International Holdings' EBITDA Margin % too high?
CK Life Sciences International Holdings' current EBITDA Margin % of 10.10% is 12% below median its 10-year median of 11.52. Over the past 10 years, this metric has ranged from a low of 6.19 to a high of 13.17. Based on the distribution chart, CK Life Sciences International Holdings ranks #267 out of 945 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CK Life Sciences International Holdings has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does CK Life Sciences International Holdings' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CK Life Sciences International Holdings ranks #267 out of 945 companies for EBITDA Margin %. This puts CK Life Sciences International Holdings in the upper half of its industry. Historically, CK Life Sciences International Holdings' own EBITDA Margin % has ranged from 6.19 to 13.17 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CK Life Sciences International Holdings and its competitors. CK Life Sciences International Holdings's current EBITDA Margin % is 10.10%, which is 12% below median its own 10-year median of 11.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CK Life Sciences International Holdings stock overvalued right now?
CK Life Sciences International Holdings (STU:LSI) has a current EBITDA Margin % of 10.10%. The stock's GF Value™ is €0.08, compared to a current price of €0.07 — trading 17.5% below its estimated fair value. The current EBITDA Margin % is 10.10%, which is 12% below median its 10-year median of 11.52. CK Life Sciences International Holdings' overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For CK Life Sciences International Holdings (STU:LSI), the current EBITDA Margin % is 10.10% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CK Life Sciences International Holdings (STU:LSI) Overvalued in 2026?
Based on GuruFocus' analysis, CK Life Sciences International Holdings stock appears to be undervalued.
The current stock price of €0.07 is trading 17.5% below its estimated GF Value™ of €0.08.
Key valuation signals for STU:LSI:
EBITDA Margin %: 10.10% (12% below median its 10-year median of 11.52)
GF Value™: €0.08 vs. price of €0.07 (17.5% below fair value)
No single metric tells the full story. See the STU:LSI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CK Life Sciences International Holdings Business Description
CK Life Sciences International Holdings Inc is an international life sciences company. It is engaged in research and development, manufacturing, commercialization, marketing and selling of health and agriculture-related products, as well as investment in a portfolio of vineyards, and various financial and investment products. Its pipeline includes Seviprotimut-L, TTX-MC138, Seviprotimut-L + TTX-MC138, TTX-RIGA, Halneuron, among others. Its segments include Agriculture-related, Nutraceutical, and Pharmaceuticals & Diagnostics R&D with the majority of the revenue deriving from Nutraceutical segment. Geographically it operates in Asia Pacific that derives the majority of the revenue and North America.
34GF Score
Get the complete analysis for STU:LSI
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:LSI has been successfully added to your 
